Seek Returns

A vs. GMAB: Agilent vs. Genmab Stock Comparison

How do Agilent (A) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Genmab (GMAB) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while GMAB is classified in Biotechnology.

Agilent (A) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Agilent (A) and Genmab (GMAB)
Profile ItemAGMAB
NameAgileThought, Inc. Class A Common StockGenmab A/S American Depositary Shares
Country/RegionUnited StatesDenmark
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization49.28 billion USD32.98 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateNovember 18, 1999June 1, 2009
Security TypeCommon StockADR

Price Performance

Cumulative Growth

A
GMAB
GSPC
Loading price history…
Agilent (A) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and Genmab (GMAB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and Genmab (GMAB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
Total Return (1Y)22.92%91.17%
Total Return (3Y, Annualized)19.33%20.70%
Total Return (5Y, Annualized)3.03%3.98%

Risk Profile

Drawdown History

A
GMAB
GSPC
Loading price history…
Agilent (A) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and Genmab (GMAB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
Volatility (1Y, Annualized)33.10%45.68%
Beta (5Y)1.220.72
Max Drawdown (5Y)-38.09%-61.79%
Avg. Volume (3M)2.25M4.09M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and GMAB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
Sharpe Ratio (1Y)0.561.90
Sortino Ratio (1Y)0.963.82

Profitability

ROE (TTM)

Both Agilent (A) at 20.97% and Genmab (GMAB) at 12.07% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max
109.18%
GMAB
12.07%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max
18.05%
GMAB
16.97%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Genmab (GMAB) at 37.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max
83.12%
GMAB
37.15%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
ROE (TTM)20.97%12.07%
ROA (TTM)8.63%8.24%
Net Margin (TTM)19.53%16.97%
Operating Margin (TTM)25.56%37.15%
Gross Margin (TTM)53.65%92.67%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and Genmab (GMAB) at 19.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and Genmab (GMAB) at -9.23% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
Revenue Growth (YoY)6.73%19.19%
Revenue Growth (3Y CAGR)0.48%21.23%
EPS Growth (YoY)3.16%-9.23%
EPS Growth (3Y CAGR)3.02%8.48%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and Genmab (GMAB) at 2.45 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GMAB
2.45
Min
0.10
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max
1.42
GMAB
0.82
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
Current Ratio (MRQ)2.052.45
Debt / Equity (MRQ)0.560.82
Net Debt / EBITDA1.152.45

Dividends

Dividend Yield (TTM)

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Genmab (GMAB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
Dividend Yield (TTM)0.59%0.00%
Dividend Payout Ratio (TTM)19.98%0.00%

Valuation

P/E Ratio (TTM)

Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max
85.34
GMAB
45.84
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max
58.18
Q3
25.77
GMAB
7.68
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Genmab (GMAB) at 5.36 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max
13.53
Q3
6.54
GMAB
5.36
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Agilent (A) vs. Genmab (GMAB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Genmab (GMAB)
MetricAGMAB
P/E Ratio (TTM)34.4745.84
P/S Ratio (TTM)6.687.68
P/B Ratio (MRQ)6.695.36
Free Cash Flow Yield (TTM)2.15%2.59%